Humana Inc. (NYSE: HUM), a leading health insurance provider based in Louisville, Kentucky, has released its financial results for the third quarter of 2024. The report highlights the company's commitment to delivering value through its insurance and healthcare services, despite facing challenges in the current economic landscape.

1. Executive Overview

Humana operates primarily in two segments: Insurance, which includes Medicare, Medicaid, and other health insurance products, and CenterWell, which focuses on pharmacy, primary care, and home solutions. The company continues to navigate a complex regulatory environment while aiming to enhance member experiences and outcomes.

2. Key Financial Highlights

Net Income: Humana reported a net income of $480 million, or $3.98 per diluted common share, for Q3 2024, a decline from $832 million or $6.71 per diluted common share in Q3 2023. For the year-to-date, net income reached $1.9 billion, down from $3.0 billion in the previous year.

Premiums Revenue: Consolidated premiums revenue surged to $28.0 billion, an 11.4% increase from $25.1 billion in Q3 2023. Year-to-date premiums revenue also rose to $84.4 billion, up from $76.1 billion.

Services Revenue: The company experienced an 8.6% increase in consolidated services revenue, reaching $1.1 billion for the quarter, while year-to-date services revenue grew to $3.3 billion.

Consolidated Benefit Ratio: The benefit ratio increased to 89.9% for Q3 2024, up from 86.6% in Q3 2023, primarily due to rising medical costs associated with Medicare Advantage and state-based contracts.

Income Statement of Humana Inc

	Nov 2023	Oct 2024
Net Income	3.01B	1.35B
Net Income to Non-controlling Interest	-9M	-2M
Profit	3.00B	1.35B
Net Income Continuing	3.05B	1.43B
Income Tax Expense	853M	554M
Pretax Income	3.90B	1.99B
Non-operating Income	-582M	-765M
Operating Income	4.48B	2.75B
Revenue	102.3B	115.0B
Costs and Expenses	97.86B	112.2B
Cost of Revenue	0	50.15B
Operating Expenses	97.86B	62.09B
Depreciation, Depletion & Amortization	0	1.41B
Selling, General & Administrative	12.91B	13.35B
Other Operating Expenses	84.95B	47.32B

3. Segment Performance

Insurance Segment

The Insurance segment's operating cost ratio improved, decreasing from 10.4% in Q3 2023 to 9.2% in Q3 2024. However, the benefit ratio rose to 90.6%, reflecting ongoing pressures from medical cost trends.

CenterWell Segment

The CenterWell segment reported a decrease in income from operations, down 4.5% to $382 million in Q3 2024. This decline can be attributed to similar factors affecting operating costs and increased competition in the healthcare marketplace.

4. Cash Flow and Liquidity

Humana's cash flow from operations decreased significantly, dropping from $11.1 billion in the year-to-date 2023 to $3.5 billion in 2024. This change was primarily due to the early receipt of Medicare premium remittances in the previous year, which did not recur in 2024.

Financing Activities

In March 2024, Humana issued $1.25 billion of unsecured senior notes due in 2031 and $1.00 billion due in 2054. The company repurchased $750 million in common shares during the period.

Cash Flow Statement of Humana Inc

	Nov 2023	Oct 2024
Net Change in Cash	1.59B	-10.03B
Net Cash from Operating Activities	5.98B	-3.64B
Operating Profit	3.00B	1.35B
Adjustment to Operating Profit	2.98B	-4.99B
Net Cash from Investing Activities	-3.62B	-3.77B
Business & Interest in Affiliates	274M	47M
Investments	2.36B	3.23B
Productive Assets	979M	494M
Net Cash from Financing Activities	-776M	-2.62B
Debt	1.14B	1.20B
Dividends	421M	434M
Equity Issuance/Repurchase	-2.06B	-1.33B
Other Financing Activities	566M	-2.05B

5. Balance Sheet Analysis

Assets: Total assets decreased from $55.9 billion in Q3 2023 to $50.0 billion in Q3 2024. Current assets also fell significantly, reflecting a reduction in cash and equivalents.

Liabilities: Total liabilities decreased from $38.9 billion to $32.4 billion, with a notable reduction in current liabilities.

Equity: Total equity increased from $17.0 billion to $17.6 billion, indicating a stable financial position despite the decline in net income.

Balance Sheet of Humana Inc

	Nov 2023	Oct 2024
Total Assets	55.90B	50.00B
Total Current Assets	38.25B	32.92B
Cash and Equivalents	15.14B	5.11B
Short-term Investments	15.14B	19.03B
Other Current Assets	6.13B	6.63B
Total Non-current Assets	17.65B	17.08B
Intangible Assets	9.54B	9.59B
Long-term Investments	1.13B	1.12B
Net PP&E	3.34B	2.69B
Other Non-current Assets	3.63B	3.66B
Total Liabilities and Equity	55.90B	50.00B
Total Liabilities	38.90B	32.38B
Total Current Liabilities	27.82B	18.72B
Accounts Payable and Accrued Liabilities	7.6B	5.91B
Current Debt	2.24B	1.13B
Current Deferred Revenue	7.53B	195M
Other Current Liabilities	10.44B	11.48B
Total Non-current Liabilities	11.07B	13.65B
Long-term Debt	9.48B	11.88B
Other Non-current Liabilities	1.59B	1.77B
Total Equity and Non-controlling Interests	17.00B	17.62B
Total Equity	16.94B	17.56B
Non-controlling Interests	55M	59M

6. Future Outlook

Humana remains committed to driving value through strategic initiatives and operational efficiencies. The company’s exit from the Employer Group Commercial Medical Products business is expected to finalize in the first half of 2025, which may lead to a more focused approach in its core segments.

Additionally, Humana continues to emphasize growth in the Medicare Advantage market, which constitutes a substantial portion of its revenue. The company is also focusing on enhancing its CenterWell services to better meet the needs of its members.

7. Conclusion

Despite facing challenges in Q3 2024, Humana Inc. is poised to continue its mission of prioritizing health for its members and stakeholders. Investors will be keenly watching how the company navigates the regulatory landscape and the evolving healthcare market in the coming quarters.

As Humana moves forward, its ability to adapt and innovate will be crucial in maintaining its leadership position in the health insurance industry.

Original filing: sec.gov